KRAS and carcinoma: The high previously reported rate could be explained by the highly selected patient populations studied, i.e., the proportion of pleomorphic carcinomas exhibiting an adenocarcinoma component yet with a low rate of other driver mutations like KRAS. Furthermore, the 5% rate found in 150 consecutive metastatic adenocarcinomas was within the range of previous reports, thereby validating our detection technique.